Tag Archives: inflammatory conditions

June, 2016

  • 22 June

    RedHill Biopharma’s Crohn’s Disease Drug Shows Potential Efficacy in Trial

    TEL-AVIV, Israel, June 22, 2016 RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced the publication of an article demonstrating the potential …

January, 2016

  • 27 January

    FDA Accepts Amgen’s BLA for its Humira Biosimilar

    THOUSAND OAKS, Calif., Jan. 25, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab). “If approved, we believe ABP 501 could serve as an important additional approved …

August, 2015

  • 21 August

    TGA Approves Hospira’s mAb Biosimilar

    MELBOURNE, Australia, Aug. 19, 2015 /PRNewswire/ — Hospira today announced that InflectraTM (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia.  This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). …